Denali Therapeutics (DNLI)

Denali Therapeutics (DNLI) Stock Price & Analysis


DNLI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$15.45 - $33.31
Previous Close$18.52
Average Volume (3M)890.93K
Market Cap
Enterprise Value$1.42B
Total Cash (Recent Filing)$1.19B
Total Debt (Recent Filing)$55.52M
Price to Earnings (P/E)-19.1
Feb 26, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding138,196,848
10 Day Avg. Volume800,116
30 Day Avg. Volume890,927
Standard Deviation0.17
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)23.60
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit13.13
Enterprise Value/Ebitda4.87
Price Target Upside182.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8



Ownership Overview

24.34% Mutual Funds
49.92% Other Institutional Investors
25.75% Public Companies and
Individual Investors


What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $15.45 and its highest was $33.31 in the past 12 months.
    What is Denali Therapeutics’s market cap?
    Currently, no data Available
    When is Denali Therapeutics’s upcoming earnings report date?
    Denali Therapeutics’s upcoming earnings report date is Feb 26, 2024 which is in 87 days.
      How were Denali Therapeutics’s earnings last quarter?
      Denali Therapeutics released its earnings results on Nov 08, 2023. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.81 by $0.09.
        Is Denali Therapeutics overvalued?
        According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Denali Therapeutics pay dividends?
          Denali Therapeutics does not currently pay dividends.
          What is Denali Therapeutics’s EPS estimate?
          Denali Therapeutics’s EPS estimate is -$0.8.
            How many shares outstanding does Denali Therapeutics have?
            Denali Therapeutics has 138,196,850 shares outstanding.
              What happened to Denali Therapeutics’s price movement after its last earnings report?
              Denali Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.81. Following the earnings report the stock price went down -4.946%.
                Which hedge fund is a major shareholder of Denali Therapeutics?
                Among the largest hedge funds holding Denali Therapeutics’s share is Flagship Pioneering Inc.. It holds Denali Therapeutics’s shares valued at 54M.


                  Company Description

                  Denali Therapeutics

                  Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.


                  Top 5 ETFs holding DNLI

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Vanguard Russell 3000 ETF
                  Strive 1000 Growth ETF
                  V-Shares US Leadership Diversity ETF
                  Up to five ETFs with an Outperform Smart Score that hold DNLI. The ETFs are listed according to market value of DNLI within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Ultragenyx Pharmaceutical
                  Ionis Pharmaceuticals
                  Sarepta Therapeutics
                  Bluebird Bio

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis